Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.63 |
| ▸ | SLC6A3 known ✓ | Q01959 | 4/20 | 0.63 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.63 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.48 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.48 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.44 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.44 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.44 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.44 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.44 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.44 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.44 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.44 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 3/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30559556 | 1.00 | SLC6A2 (0.63) | SLC6A2SLC6A3SLC6A4PNMTIDO1 | |
| SCHEMBL13692527 | 0.98 | SLC6A2 (0.66) | SLC6A2SLC6A3SLC6A4PNMTIDO1 | |
| SCHEMBL268275 | 0.98 | SLC6A2 (0.66) | SLC6A2SLC6A3SLC6A4PNMTIDO1 | |
| SCHEMBL8029239 | 0.98 | SLC6A2 (0.66) | SLC6A2SLC6A3SLC6A4PNMTIDO1 | |
| Methane SCHEMBL20481902 | 0.96 | SLC6A2 (0.63) | SLC6A2SLC6A3SLC6A4PNMTIDO1 | |
| SCHEMBL2857779 | 0.82 | SLC6A2 (0.61) | SLC6A2SLC6A3SLC6A4TAAR1MAOA | |
| SCHEMBL13692532 | 0.82 | PNMT (0.57) | SLC6A2SLC6A3SLC6A4PNMTIDO1 | |
| SCHEMBL3885817 | 0.82 | PNMT (0.57) | SLC6A2SLC6A3SLC6A4PNMTIDO1 | |
| SCHEMBL17407624 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A3SLC6A4PNMTIDO1 | |
| Hydrochloric Acid SCHEMBL14660772 | 0.81 | SLC6A2 (0.51) | SLC6A2SLC6A3SLC6A4PNMTIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4122914-B1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI PHARMTECH INC (TW) | 2023-08-16 | — | — | EP | disclosed |
| EP-4215517-A1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI Pharmtech Inc. (CN) | 2023-07-26 | — | — | EP | disclosed |
| US-11608312-B1 | Compound and method for preparation of lisdexamfetamine | SCI PHARMTECH INC. (TW) | 2023-03-21 | — | — | US | disclosed |
| US-20230084232-A1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI PHARMTECH INC. (TW) | 2023-03-16 | — | — | US | disclosed |
| EP-4122914-A1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI Pharmtech Inc. (CN) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021074309-A1 | 1-(3-QUINOLYL)-3,4-DIHYDROISOQUINOLINE DERIVATIVES AS FUNGICIDES FOR COMBATING SPECIFIC PHYTOPATHOGENS | SYNGENTA CROP PROTECTION AG (CH) | 2021-04-22 | — | — | WO | disclosed |
| US-10544434-B2 | Process for the preparation of lisdexamfetamine and related derivatives | NORAMCO, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| WO-2017003721-A1 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE AND RELATED DERIVATIVES | NORAMCO, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| US-20160376618-A1 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE AND RELATED DERIVATIVES | NORAMCO, LLC | 2016-12-29 | — | — | US | disclosed |
| US-8614346-B2 | Methods and compositions for preparation of amphetamine conjugates and salts thereof | CAMBREX CHARLES CITY, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120190880-A1 | METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF | BLUE OWL CAPITAL CORPORATION, AS NEW AGENT | 2012-07-26 | — | — | US | disclosed |
| WO-2010148305-A1 | METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF | CAMBREX CHARLES CITY, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-7705184-B2 | Method of making amphetamine | CAMBREX CHARLES CITY, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090292143-A1 | METHOD OF MAKING AMPHETAMINE | CAMBREX CHARLES CITY (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190880-A1 | METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF | PNMT, COMT, DDT | SLC6A2 25/4885SLC6A3 9/4885SLC6A4 101/4885 |
| US-10544434-B2 | Process for the preparation of lisdexamfetamine and related derivatives | COMT, MGAM, GAA | SLC6A2 14/4885SLC6A3 4/4885SLC6A4 9/4885 |
| US-11608312-B1 | Compound and method for preparation of lisdexamfetamine | COMT, CYP2D6, SLC6A3 | SLC6A2 11/4885SLC6A3 3/4885SLC6A4 54/4885 |
| US-20160376618-A1 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE AND RELATED DERIVATIVES | COMT, MGAM, GAA | SLC6A2 14/4885SLC6A3 4/4885SLC6A4 9/4885 |
| US-20230084232-A1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | COMT, CYP2D6, SLC6A3 | SLC6A2 11/4885SLC6A3 3/4885SLC6A4 54/4885 |
| US-20090292143-A1 | METHOD OF MAKING AMPHETAMINE | COMT, PNMT, CES2 | SLC6A2 40/4885SLC6A3 7/4885SLC6A4 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.